Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.
Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
4funds adding
5new positions
$756.8Mheld by those funds
AIThis scan
Compared the 2026-03-31 and 2025-12-31 13F-HR windows for Berkshire Hathaway, Bridgewater Associates, Renaissance Technologies, Citadel Advisors, and Two Sigma Investments. All five filings parsed cleanly. After excluding ETFs, non-US ADRs, sub-$1B market caps, mega-cap retail favorites, and names with earnings within seven trading days, 893 CUSIPs passed the raw acceleration filter; five mid-cap operating companies make the final list — each one where two or more managers (including at least one Bridgewater entry as the slowest-moving signal in our active set) opened new positions or materially expanded existing ones in Q1, while retail attention remains thin.
The most notable convergence pattern: Bridgewater opened brand-new positions in both ENPRO (NPO) and ESCO Technologies (ESE) while Citadel and Two Sigma simultaneously initiated new positions in the same two names. A four-fund overlap on two mid-cap industrials — one a stealth leading-edge semicap services play, the other a Navy/aerospace defense electronics franchise — is the kind of pattern that resists dismissal as quant noise. Berkshire's Q1 activity was concentrated in names already widely held (KO, AXP, BAC) or already covered in prior weeklies (STZ, DPZ), so it does not anchor any name in this run.
How this scan was run
Per-CUSIP deltas computed by summing share counts across multi-row subsidiary holdings within each filing (Berkshire's BAC, AAPL, AXP rows are split across operating subs and were aggregated). PUT-option holdings excluded; CALL holdings counted. Acceleration filter required: net adders > net sellers across the configured fund list, AND either aggregate Q/Q share growth >=25% or >=2 funds opening new positions, AND single-fund dominance not exceeding 80% of total positive delta (none of the final five violated this; HLI was the tightest at 77%). Mega-cap retail favorites (AAPL, MSFT, NVDA, GOOG/GOOGL, META, AMZN, TSLA) excluded by CUSIP. Quant managers (Renaissance, Two Sigma) and Citadel weighted lower in thesis writing per the standard intra-quarter trading caveat; Bridgewater entries given primary weight as the slowest-moving manager active in the final five (Berkshire did not anchor any name this run). Yahoo Finance blocked direct WebFetch (403); live prices and market caps sourced via search aggregators reflecting the most recent verifiable quote (May 14-16 for HLI/EHC/AWI/ESE; mid-March for NPO due to thin search coverage). avgEntryPriceEstimate derived from valueUsd / sharesHeld aggregated at quarter-end across supporting funds — an estimate, not a verified cost basis (13F does not report cost basis). news30DayCount values are order-of-magnitude estimates from search aggregator coverage rather than an API count; googleTrendsScore and optionsCallPutOiRatio left null where not verifiable. isOnRetailHotlist verified false for all five — none surfaced in WSB/StockTwits trending searches. All 5 funds returned holdings successfully; no failures.
#1
HLI
Houlihan Lokey, Inc.
FinancialsMkt cap $10.7BNext earnings Jul 28, 2026
Price
$153.17
Est. fund entry
$143.62+6.6%
Shares held
624.8K
Position value
$89.7M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
3.60K
20.5K
+471.1%
Citadel Advisors
81.9K
498.0K
+508.1%
Two Sigma Investments
—
106.3K
New position
Retail attention 2 of 2 signals quiet
Google Trends—n/a
News, 30 days14 articlesquiet
Call/put OI—n/a
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Houlihan dominates middle-market M&A advisory and leads independent restructuring practice — two countercyclical legs that absorb each other across deal regimes. Bridgewater scaled its position +471%, Citadel +508%, and Two Sigma opened a new 106k-share holding in Q1, even as the May 6 FY26 print missed by $0.16 and management flagged cross-border and software-deal softness. The restructuring backlog tied to private-credit refis is the structural offset that hasn't shown up in sell-side models. The stock has reset to $153 from a 52-week high of $211.78, giving the multi-fund add a clean cost basis near smart-money entry. Catalyst retail hasn't priced: announced US M&A volume re-accelerating into 2H26 plus restructuring revenue conversion visible in the July 28 Q1 FY27 print.
What would prove it wrong
Continued cross-border deal drag and a second consecutive fiscal-quarter miss on July 28 would invalidate the thesis. Bearish technical setup and analyst downgrades may persist two more quarters before the restructuring leg becomes visible in reported results.
#2
EHC
Encompass Health Corporation
Health CareMkt cap $10.6BNext earnings Jul 29, 2026
Price
$106.64
Est. fund entry
$96.73+10.2%
Shares held
3.05M
Position value
$294.9M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
35.4K
46.4K
+31.1%
Renaissance Technologies
68.2K
265.0K
+288.6%
Citadel Advisors
125.1K
515.1K
+311.8%
Two Sigma Investments
804.9K
2.22M
+176.1%
Retail attention 2 of 2 signals quiet
Google Trends—n/a
News, 30 days9 articlesquiet
Call/put OI—n/a
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Encompass operates the largest US inpatient rehabilitation hospital network — a quasi-duopoly business with a multi-year de novo hospital pipeline and a clear aging-demographic tailwind. All four non-Berkshire funds added in Q1: Two Sigma +176% to 2.22M shares (the dominant size), Citadel +312%, Renaissance +289%, Bridgewater +31%. Q1 revenue grew 9% and adjusted EBITDA 11%; UBS and Barclays both raised price targets to $150. The stock has cooled into the $106 range against a 17.8x earnings multiple that sits below the US healthcare average of 22.1x. Catalyst retail hasn't priced: continued mid-single-digit volume growth, de novo openings hitting EBITDA contribution, and stable Medicare rate-setting into the 2027 update.
What would prove it wrong
Medicare reimbursement reform is the standing tail risk for the entire post-acute sub-sector. Staffing cost re-acceleration could compress margins; valuation already discounts a multi-year smooth setup, so any operational hiccup re-rates faster than the upside leg.
#3
NPO
Enpro Inc.
IndustrialsMkt cap $6.1BNext earnings Aug 5, 2026
Price
$254.14
Est. fund entry
$250.65+1.4%
Shares held
94.9K
Position value
$23.8M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
—
1.66K
New position
Renaissance Technologies
24.1K
50.1K
+107.9%
Citadel Advisors
4.65K
13.4K
+188.4%
Two Sigma Investments
—
29.7K
New position
Retail attention 2 of 2 signals quiet
Google Trends—n/a
News, 30 days7 articlesquiet
Call/put OI—n/a
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
ENPRO is two businesses: Advanced Surface Technologies (wafer-handling and chamber-cleaning services to leading-edge fabs) and Sealing (aerospace and industrial). AST is a stealth semicap leverage play wrapped in a low-volatility ticker — most retail screens it as a sealing company. Q1 beat and management raised FY26 guidance across all key metrics; Bridgewater and Two Sigma both opened brand-new positions while Citadel added +188% and Renaissance +108%. A four-fund convergence on a $6B mid-cap industrial is uncommon. Catalyst retail hasn't priced: AST organic revenue inflection as 2H26 leading-edge fab tool installs convert to service-contract revenue, plus M&A pipeline execution under the Enpro 3.0 framework.
What would prove it wrong
AST revenue is concentrated across a small number of fab customers; one push-out compresses near-term visibility. Sealing is tied to aerospace OEM build rates and the industrial cycle. The multiple has already expanded modestly off the recent raise.
#4
ESE
ESCO Technologies Inc.
IndustrialsMkt cap $8.0BNext earnings Aug 10, 2026
Price
$292.96
Est. fund entry
$281.37+4.1%
Shares held
223.3K
Position value
$62.8M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
4.36K
19.1K
+337.5%
Citadel Advisors
—
94.8K
New position
Two Sigma Investments
—
109.4K
New position
Retail attention 2 of 2 signals quiet
Google Trends—n/a
News, 30 days6 articlesquiet
Call/put OI—n/a
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
ESCO operates three segments: utility test instruments, RF/EMC test chambers for defense and aerospace, and filtration for Navy submarines and aerospace platforms. The Navy submarine content and aerospace filtration carry multi-year program visibility that is underappreciated for an $8B mid-cap. Bridgewater scaled its position +337%, and Citadel and Two Sigma both opened brand-new positions in Q1. Q2 beat and management raised FY26 EPS guidance to $8.00-$8.25 (33-37% growth) — yet the stock pulled back ~14% from its early-May high near $342 to ~$293, opening a clean re-entry window around the multi-fund cost basis. Catalyst retail hasn't priced: Navy shipbuilding cadence plus RF test chamber demand from radar/EW programs converting to revenue in the August Q3 print.
What would prove it wrong
Customer concentration in the utility test instruments segment. Defense budget timing risk if continuing resolutions delay contract awards. Aerospace OEM exposure ties one leg to the commercial build cycle.
#5
AWI
Armstrong World Industries, Inc.
IndustrialsMkt cap $6.6BNext earnings Jul 28, 2026
Price
$155.17
Est. fund entry
$164.80-5.8%
Shares held
1.73M
Position value
$285.6M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
17.6K
30.8K
+74.3%
Renaissance Technologies
117.3K
118.7K
+1.2%
Citadel Advisors
548.8K
800.0K
+45.8%
Two Sigma Investments
237.9K
783.8K
+229.4%
Retail attention 2 of 2 signals quiet
Google Trends—n/a
News, 30 days7 articlesquiet
Call/put OI—n/a
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Armstrong is the duopoly leader in commercial ceiling grid — a structurally pricing-rational market where commercial reno cycles deliver predictable cash flow. Two Sigma scaled +229%, Citadel +46%, Bridgewater +74%, with Renaissance flat-to-slightly-up. 2026 guidance of $1.745-$1.785B revenue and $600-$620M adjusted EBITDA implies high-single- to low-double-digit growth with operating leverage. The stock sits at $155 against a 52-week high of $206 and a 52-week low of $149 — pinned near the bottom of its range, giving the multi-fund accumulation a meaningful margin of safety. Average entry across supporting funds is roughly $165, modestly above current price. Catalyst retail hasn't priced: commercial office reno cycle continuing into 2H26, mineral fiber pricing actions flowing through Q3/Q4 margins, and the $375-$395M FCF guide funding buybacks and acquisitions.
What would prove it wrong
Office vacancy rates continuing to pressure commercial reno demand. Raw materials inflation could squeeze near-term margins. The stock has lagged for valid reasons and may require a multi-quarter range break before institutional accumulation drives a re-rating.
Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds
and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones —
while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a
new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.